Effect of morphine pump in prepontine cistern via lumbar approach for intractable head and neck cancer pain.
10.11817/j.issn.1672-7347.2025.250049
- Author:
Wenjie ZHANG
1
,
2
;
Bohua YIN
3
;
Xinning LI
1
;
Jiaxin LEI
1
;
Yanying XIAO
1
;
Yaping WANG
1
;
Dingquan ZOU
1
,
4
Author Information
1. Department of Pain Management, Second Xiangya Hospital, Central South University, Changsha
2. 1716544927@qq.com.
3. Department of Pain Management, Central Hospital of Yongzhou, Yongzhou 425006, China.
4. dingquan.zou@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
head and neck cancer;
intractable cancer pain;
intrathecal targeted drug delivery;
morphine pump;
prepontine cistern
- MeSH:
Humans;
Morphine/administration & dosage*;
Male;
Female;
Middle Aged;
Head and Neck Neoplasms/surgery*;
Analgesics, Opioid/administration & dosage*;
Cancer Pain/drug therapy*;
Pain, Intractable/etiology*;
Aged;
Adult;
Infusion Pumps, Implantable;
Pain Management/methods*
- From:
Journal of Central South University(Medical Sciences)
2025;50(6):995-1001
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:Managing patients with refractory head and neck cancer pain is one of the more challenging issues in clinical practice, and traditional intrathecal drug delivery also fails to provide adequate analgesia. There are currently no comprehensive and effective treatment methods. This study aims to observe the efficacy and safety of treating intractable head and neck cancer pain with morphine pump via lumbar approach to the prepontine cistern.
METHODS:A total of 18 patients with intractable head and neck cancer pain treated with prepontine cistern morphine pumps were selected from the Department of Pain Management, Second Xiangya Hospital, Central South University between September 2019 and July 2023. Statistical analysis was performed on patients' preoperative and postoperative (1 week, 1 month, and 2 months after surgery), Numerical Rating Scale (NRS) scores, Self-Rating Depression Scale (SDS) scores, daily oral morphine consumption, the number of daily breakthrough pain episodes, and postoperative daily intrathecal morphine dosage.
RESULTS:The NRS scores, SDS scores, daily oral morphine consumption, and the number of daily breakthrough pain episodes of patients at each time point after surgery were significantly lower than before surgery (all P<0.05). With the gradual increase in the dosage of intrathecal morphine, the daily oral morphine consumption of patients at each postoperative time point was significantly reduced compared to preoperative levels (all P<0.05). The complications related to the operation were mild, including nausea in 5 cases (31.3%), headache in 2 cases (12.5%); hypotension, urine retention, hypersomnia and constipation in 1 case (6.3% each), and no serious adverse events occurred. All improved and were discharged after symptomatic treatment.
CONCLUSIONS:The implantation of prepontine cistern morphine pump effectively controls intractable head and neck cancer pain, demonstrating characteristics of minimal invasiveness, mild side effects, and low medication dosage under the premise of standardized procedures.
